Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Department of Justice
Citi
Merck
Cipla
Boehringer Ingelheim
Medtronic
Fuji
UBS
Farmers Insurance

Generated: October 23, 2017

DrugPatentWatch Database Preview

Gd Searle Llc Company Profile

« Back to Dashboard

What is the competitive landscape for GD SEARLE LLC, and what generic alternatives to GD SEARLE LLC drugs are available?

GD SEARLE LLC has forty-two approved drugs.

There are eight US patents protecting GD SEARLE LLC drugs.

There are ninety-four patent family members on GD SEARLE LLC drugs in thirty countries and thirty-three supplementary protection certificates in ten countries.

Summary for Applicant: Gd Searle Llc

International Patents:94
US Patents:8
Tradenames:37
Ingredients:25
NDAs:42
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc
LIDOCAINE HYDROCHLORIDE
lidocaine hydrochloride
INJECTABLE;INJECTION083135-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
POTASSIUM CHLORIDE
potassium chloride
INJECTABLE;INJECTION086220-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
LOMOTIL
atropine sulfate; diphenoxylate hydrochloride
SOLUTION;ORAL012699-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
FLAGYL
metronidazole
TABLET;ORAL012623-003Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Gd Searle Llc
ARTHROTEC
diclofenac sodium; misoprostol
TABLET, DELAYED RELEASE;ORAL020607-002Dec 24, 1997ABRXYesYes► Subscribe► Subscribe► Subscribe
Gd Searle Llc
ENOVID
mestranol; norethynodrel
TABLET;ORAL010976-008Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
AMMONIUM CHLORIDE
ammonium chloride
INJECTABLE;INJECTION086205-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
ALDACTONE
spironolactone
TABLET;ORAL012151-008Dec 30, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
NORPACE CR
disopyramide phosphate
CAPSULE, EXTENDED RELEASE;ORAL018655-002Jul 20, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Gd Searle Llc
ALDACTONE
spironolactone
TABLET;ORAL012151-010Dec 30, 1983ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Gd Searle Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-001Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
CYTOTEC
misoprostol
TABLET;ORAL019268-001Dec 27, 1988► Subscribe► Subscribe
Gd Searle Llc
INSPRA
eplerenone
TABLET;ORAL021437-001Sep 27, 2002► Subscribe► Subscribe
Gd Searle Llc
TATUM-T
copper
INTRAUTERINE DEVICE;INTRAUTERINE018205-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-001Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
CYTOTEC
misoprostol
TABLET;ORAL019268-003Sep 21, 1990► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
SYNAREL
nafarelin acetate
SPRAY, METERED;NASAL019886-001Feb 13, 1990► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GD SEARLE LLC drugs

Drugname Dosage Strength Tradename Submissiondate
diclofenac sodium and misoprostol
Delayed-release Tablets50 mg/0.2 mg
ARTHROTEC
6/29/2009
diclofenac sodium and misoprostol
Delayed-release Tablets75 mg/0.2 mg
ARTHROTEC
11/28/2008
eplerenone
Tablets25 mg and 50 mg
INSPRA
9/27/2006

Non-Orange Book Patents for Gd Searle Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,534,089 Uniform drug delivery therapy► Subscribe
6,863,902 Immediate release eplerenone compositions► Subscribe
6,592,902 Controlled release eplerenone compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Gd Searle Llc Drugs

Country Document Number Estimated Expiration
Israel143301► Subscribe
World Intellectual Property Organization (WIPO)9737640► Subscribe
Eurasian Patent Organization004064► Subscribe
TaiwanI234459► Subscribe
Spain2166988► Subscribe
World Intellectual Property Organization (WIPO)0051642► Subscribe
Spain2250803► Subscribe
South Korea20000005230► Subscribe
South Africa200107779► Subscribe
MexicoPA01009035► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Gd Searle Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
04C/008Belgium► SubscribePRODUCT NAME: EPLERENONE; NATIONAL REGISTRATION NO/DATE: 241 IS 188 F3 20041220; FIRST REGISTRATION: NL RVG 29963 20040316
/2015Austria► SubscribePRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
80024Netherlands► SubscribePRODUCT NAME: GADOBEENZUUR,DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN ALKA- LIMETAAL, AARDALKALIMETAAL, OF BASISCH GEPROTONEERD AMINOZUUR OF VAN EEN ALKYLAMMONIUM-, ALKANOLAMMONIUM- OF POLYHYDROXYAL- KYLAMMONIUMZOUT, IN HET BIJZONDER DIMEGLUMINI GADOBENAS; NAT. REGISTRATION NO/DATE: RVG 22324 19980706; FIRST REGISTRATION: GB PL 06099/0006 19970722
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
US Department of Justice
Queensland Health
Medtronic
Merck
McKinsey
Boehringer Ingelheim
Chubb
Novartis
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot